Upharmacia April 2017
CIS REGION PHARMA
NEWS
A rmenia
The Union of producers
and importers of drugs of
Armenia has prepared the Draft Codex of
good practice for pharmaceutical companies.
The document was created on the basis of
the Codex of the International Federation
of Pharmaceutical Manufactures and
Associations (IFPMA).
— —
A zerbaijan
Investment company
Azersun Holding plans to possess
20-30% of the pharmaceutical market of
Azerbaijan, the CEO of the company stated.
Azersun Holding jointly with Azaerbaijani
Investment Company and Iranian Tamin
Pharmaceutical Investment Company is
constructing the pharmaceutical plant in
Pirallakhinsky industrial park.
— —
B elarus
Indian company NATCO
Pharma Ltd will support the
development of the first in Belarus laboratory
of small chemical synthesis in Vitebsk.
The laboratory will serve as research and
development center competent in the
development and transfer of technologies for
the synthesis of expensive pharmaceutical
substances.
— —
K azakhstan
Kazakh pharmaceutical
company Abdi Ibrahim Global
Pharm (part of Turkish corporation Abdi
Ibrahim) started export of medicines for
the treatment of hepatitis and diabetes in
— —
10
Azerbaijan and Georgia. The company plans
to considerably increase its exports in the CIS
countries in the following years.
R ussia
According to the survey
of the consulting group IPT, the
representatives of Russian pharmaceutical
market expect it to grow by 6-7% y-o-y in 2017
(in rubles), and by 9% y-o-y in 2018. In values,
the annual growth in these years is envisaged
at 4-6% y-o-y
— —
— — Russian company Generium and International
biopharmaceutical company Shire have
created a joined company SG Biotech for the
sale of drugs for the treatment of hemophilia.
Currently , the company controls over 70% of
hemophilia segment of the hospital market
— — Russian subsidiary of Merck signed the
agreement with Kaluga pharmaceutical
cluster on the development of life sciences
technologies in Kaluga region
— — Japanese company Mitsui will buy 10% share
in R-Pharm for about USD 200 mio. The deal
is expected to be closed in Sep 2017. Further
expansion of the package is under discussion.
— — Within the large-scale investment program
Protec group of companies acquired 100% of
shares of Rafarma pharmaceutical industrial
complex
— — According to the data of pharmaceutical
company Nativa, in 2017, the market of
pulmonological drugs will worth more
than RUB 14bn. Three foreign companies
(AstraZeneca, GSK and Boehringer Ingelheim)
possess more than 83% of the market.
www.upharma-c.com